Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AbobotulinumtoxinA is a purified neurotoxic protein produced by the bacterium Clostridium botulinum. It is a subtype of botulinum toxin type A and acts as a neuromuscular blocker. The drug works by inhibiting acetylcholine release at the neuromuscular junction, resulting in temporary muscle paralysis or relaxation. AbobotulinumtoxinA is primarily used to treat cervical dystonia (spasmodic torticollis), spasticity of upper and lower limbs in adults and children aged 2 years and older, and to temporarily improve the appearance of glabellar lines (frown lines) between the eyebrows. It may also be used off-label for other focal dystonias such as blepharospasm[1][3][4][5][7][8]. The effects are reversible over several months as nerve terminals regenerate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on abobotulinumtoxinA.